<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472808</url>
  </required_header>
  <id_info>
    <org_study_id>DM Thesis</org_study_id>
    <nct_id>NCT02472808</nct_id>
  </id_info>
  <brief_title>A Trial to Compare Two Methods of Obtaining Tissue for Diagnosis of Sarcoidosis Namely the Conventional Method or the Ultrasound Guided Method</brief_title>
  <official_title>Diagnostic Utility of EBUS-TBNA Versus Conventional TBNA With Rapid on Site Evaluation in the Diagnosis of Sarcoidosis: a Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial compares the yield of cTBNA (conventional Transbronchial Needle Aspiration) versus
      the EBUS-TBNA (Endobronchial Ultrasound guided TBNA) for obtaining cytology when they are
      combined with endobronchial biopsy and transbronchial lung biopsy and rapid onsite
      examination (ROSE) of the obtained smears in the diagnosis of suspected sarcoidosis patients
      visiting our hospital for evaluation of mediastinal lymphadenopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is investigator initiated, prospective, unblinded randomized study comparing
      conventional TBNA with EBUS-TBNA for obtaining tissue samples from mediastinal lymph nodes
      for the diagnosis of sarcoidosis when combined with transbronchial lung biopsy and
      endobronchial biopsy. It will be conducted on 80 consecutive patients with suspected
      sarcoidosis presenting to Department of Pulmonary Medicine and Sleep Disorders in AIIMS (All
      India Institute of Medical Sciences), New Delhi. This study will help to know whether EBUS
      (Endobronchial Ultrasound guided) or conventional TBNA is better for obtaining tissue samples
      from mediastinal lymph nodes for the diagnosis of sarcoidosis. It will also help to know the
      value of adding rapid onsite evaluation of the cytology smears to both the procedures. It
      will also help to determine the overall yield of different procedures when they are combined
      for obtaining tissue samples for a diagnosis of sarcoidosis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Yield of Conventional TBNA vs EBUS TBNA with or without ROSE</measure>
    <time_frame>6 months</time_frame>
    <description>Diagnostic Yield is defined as the number of patients with presence of non caseating granuloma on cytology smear divided by total number of sarcoidosis patient expressed as percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yield of EBUS-TBNA in Conventional TBNA with or without ROSE negative patients</measure>
    <time_frame>6 months</time_frame>
    <description>Yield is defined as the number of patients with presence of non caseating granuloma on cytology smear divided by total number of sarcoidosis patient expressed as percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of conventional TBNA to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of conventional TBNA when combined with ROSE to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of EBUS-TBNA to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of EBUS-TBNA when combined with ROSE to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of conventional TBNA to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of conventional TBNA when combined with ROSE to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of EBUS-TBNA to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of EBUS-TBNA when combined with ROSE to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of conventional TBNA to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of conventional TBNA when combined with ROSE to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of EBUS-TBNA to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of EBUS-TBNA when combined with ROSE to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of conventional TBNA in the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of conventional TBNA when combined with ROSE in the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of EBUS-TBNA in the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of EBUS-TBNA when combined with ROSE in the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Sensitivity of endobronchial biopsy to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Specificity of endobronchial biopsy to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Positive predictive value of endobronchial biopsy to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Negative predictive value of endobronchial biopsy in the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Sensitivity of transbronchial lung biopsy to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Specificity of transbronchial lung biopsy to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Positive predictive value of transbronchial lung biopsy to detect Non Caseating Granuloma for the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Negative predictive value of transbronchial lung biopsy in the diagnosis of Sarcoidosis</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>cTBNA without ROSE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who will undergo conventional TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cTBNA with ROSE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who will undergo conventional TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBUS-TBNA without ROSE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who will undergo EBUS-TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBUS-TBNA with ROSE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who will undergo EBUS-TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cTBNA without ROSE</intervention_name>
    <description>Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy</description>
    <arm_group_label>cTBNA without ROSE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cTBNA with ROSE</intervention_name>
    <description>Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy</description>
    <arm_group_label>cTBNA with ROSE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EBUS-TBNA without ROSE</intervention_name>
    <description>Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy</description>
    <arm_group_label>EBUS-TBNA without ROSE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EBUS-TBNA with ROSE</intervention_name>
    <description>Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy</description>
    <arm_group_label>EBUS-TBNA with ROSE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years and suspected Stage 1 (mediastinal or hilar Lymphadenopathy (LAP)) or
             Stage 2 ( LAP and parenchymal abnormalities) sarcoidosis

          -  Significant mediastinal LAP (Short Axis Diameter more than 10mm)

          -  Lymph Node (LN) enlargement in station 4, 7, 10 or 11 and CT chest findings consistent
             with sarcoidosis.

          -  With or without supportive evidence of sarcoidosis - hypercalcemia, calciuria, raised
             ACE levels or restriction/obstruction on Pulmonary Function Tests (PFT).

        Exclusion Criteria:

          -  Obvious other organ involvement with possibility to confirm granuloma with minimally
             invasive diagnostic procedure (Skin biopsy, superficial lymph nodes, Lofgren's
             Syndrome)

          -  Sarcoidosis Stage 3 and 4

          -  Mediastinal Nodes less than 10 mm in short axis diameter

          -  Absence of right paratracheal and subcarinal Lymph node enlargement more than 1 cm in
             short axis diameter

          -  Those who received empiric Steroid for &gt;2 weeks in preceding 3 months

          -  Contraindication to bronchoscopy and TBNA (Coagulopathy, Hypoxemia)

          -  Unwilling to give consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashesh Dhungana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashesh Dhungana, MD</last_name>
    <phone>00919953586175</phone>
    <email>asheshdhungana12@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Randeep Guleria, DM</last_name>
    <phone>00919810184738</phone>
    <email>randeepguleria2002@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashesh Dhungana, MD</last_name>
      <phone>09953586175</phone>
      <email>asheshdhungana12@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Randeep Guleria, DM</last_name>
      <phone>09810184738</phone>
      <email>randeepg@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ashesh Dhungana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randeep Guleria, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2015</study_first_posted>
  <last_update_submitted>July 6, 2015</last_update_submitted>
  <last_update_submitted_qc>July 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, New Delhi</investigator_affiliation>
    <investigator_full_name>Dr. Ashesh Dhungana</investigator_full_name>
    <investigator_title>Senior Resident, Department of Pulmonary Medicine and Sleep Disorders</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

